COMMUNIQUÉS West-GlobeNewswire

HNL Lab Medicine Earns Record 12 Reputation 800 Awards for Patient Experience Excellence
26/03/2026
ALLENTOWN, Pa., March 26, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine has achieved a record milestone in patient experience, with 12 of its Patient Service Centers (PSCs) earning the prestigious Reputation 800 Award in [...]
HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
26/03/2026
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics NEW YORK and VIENNA, March 26, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “ [...]
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
26/03/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in Acumen’s Enhanced [...]
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
26/03/2026
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth [...]
Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
26/03/2026
San Antonio Center Cleared to Commence Commercial Sales of Normal Source Plasma State of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue [...]
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
26/03/2026
Insurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage Concurrently, Vivos Implements Cost Reduction Initiatives Related to [...]
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
26/03/2026
– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company plans to initiate [...]
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026 Phase 2 IRIS trial for ML-004 for autism [...]
Notification of managers’ transactions
26/03/2026
ANNOUNCEMENT NO. 304 26 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notifications pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Sironax Appoints Clive Wang to Board of Directors
26/03/2026
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare [...]
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
26/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the filing of two new patent applications that further expand the [...]
BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD
26/03/2026
BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental [...]
Fangzhou Inc. Appoints Healthcare Industry Veteran Wang Haijiao as Chief Executive Officer Following a Year of Record Growth and Profitability
26/03/2026
SHANGHAI, March 26, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, today announced the appointment of Mr. WANG Haijiao [...]
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
26/03/2026
Intranasal oxytocin blocks the release of calcitonin gene-related peptide ( CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and trigeminal neuralgia TNX [...]
Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
26/03/2026
OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary [...]
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
26/03/2026
Patent strengthens competitive position in European drug screening market and reinforces Company's European intellectual property protection NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ( [...]
Avicanna Subsidiary SMGH Completes First Commercial Export to Australia
26/03/2026
This marks the first commercial export of organic certified flower for SMGH The export represents the 21 st market for SMGH and 24 th market for all Avicanna products TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Avicanna [...]
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
26/03/2026
– Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe – Advances Proposed Expedited Regulatory Approval Pathways in [...]
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
26/03/2026
JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents [...]

Pages